Patents by Inventor Roger AOKI

Roger AOKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activatable clostridial toxins
    Patent number: 7740868
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: June 22, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100151494
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: June 17, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7723480
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 25, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Fret protease assays for botulinum serotype A/E toxins
    Patent number: 7718766
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: May 18, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • CHIMERA BOTULINUM TOXIN TYPE E
    Publication number: 20100121042
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: May 13, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Substrates useful for FRET protease assays for botulinum serotype A/E toxins
    Patent number: 7709608
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: May 4, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7705124
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: April 27, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Leucine-based motif and Clostridial neurotoxins
    Patent number: 7705125
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: April 27, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 7691983
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 7691974
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
  • FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY
    Publication number: 20100081155
    Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.
    Type: Application
    Filed: October 22, 2009
    Publication date: April 1, 2010
    Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki
  • FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY
    Publication number: 20100081156
    Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.
    Type: Application
    Filed: October 22, 2009
    Publication date: April 1, 2010
    Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081158
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081157
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075358
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075346
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075357
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • SUBSTRATES USEFUL FOR FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TXOINS
    Publication number: 20100069610
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: December 11, 2006
    Publication date: March 18, 2010
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET protease assays for botulinum serotype A/E toxins
    Patent number: 7678550
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: March 16, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Fluorescence polarization assays for determining clostridial toxin activity
    Patent number: 7674601
    Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: March 9, 2010
    Assignee: Allergan, Inc.
    Inventors: Dudley J. Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki